製品番号: HY-163828

PPA24

カスタマーレビュー

Based on 1 Customer Validation

PPA24 is a PP2A activator with a K_D of 8.465 μM for PP2ACα. PPA24 induces cancer cell death via apoptosis. PP2ACα induces ROS generation and decreases the level of c-Myc expression. PPA24 can be used to study colorectal cancer (CRC), Folinic acid (HY-17556), 5-Fluorouracil (HY-90006), and Oxaliplatin (HY-17371) (FOLFOX)-resistant CRC, and melanoma cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.09%
CAS 番号: 3035032-77-7
分子式: C₂₂H₂₇BrClN₅S
分子量:508.91

保管条件:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

PPA24 構造式

CAS 番号: 3035032-77-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

PP2A

GSK-3α

GSK-3β

GSK-3 アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

体外実験

PPA24 (0.5-50 μM, 48 h) shows cytotoxicity against HCT116, HT29, DLD1, SW480, FOLFOX HCT116 and FOLFOX HT29, with IC₅₀s of 3.95, 6.75, 3.45, 3.64, 2.63 and 3.04 μM, respectively, shows weak cytotoxicity against HaCaT, with IC₅₀ of 10.04 μM^[1].
PPA24 (2.5-10 μM, 24 h) induces apoptosis in HCT116, HT29, FOLFOX HCT116, FOLFOX HT29 cells^[1].
PPA24 (2.5-5 μM, 6-12 h) stimulates ROS generation in HCT116 cells^[1].
PPA24 (2.5-5 μM, 24 h) decreases the level of c-Myc expression in HCT116, FOLFOX HCT116 cells^[1].
PPA24 (0.1-10 μM, 48 h) shows a synergistic effect and Gemcitabine (HY-17026) or Cisplatin (HY-17394) with HCT116 cells^[1].
PPA24 shows cytotoxicity against SK-MEL-2, SK-MEL-28, A375, Mel1241, and 451Lu cells with IC₅₀s in the range of 5.99-14.45 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

HCT116, HT29, FOLFOX HCT116, FOLFOX HT29
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

24 h
Result:

Induced apoptosis.

Western Blot Analysis^[1]

Cell Line:

HCT116, FOLFOX HCT116
Concentration:

2.5 μM, 5 μM
Incubation Time:

24 h
Result:

Decreased the level of c-Myc expression, did not increase the level of degradation of c-Myc.
Reduced the protein expression level of GSK-3α/β but did not change p-GSK-3α/β (S21/9).

体内実験

PPA24 (nanoformulation (Nano-PPA24)) (6 mg/kg, i.v., three times per week, 23 days) inhibits tumor growth with no significant changes in body weight in HCT116 xenografts nude mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HCT116 (1.5 × 10⁶) xenografts nude mice model^[1]
Dosage:

6 mg/kg, nanoformulation (Nano-PPA24)
Administration:

i.v., three times per week, 23 days
Result:

Inhibited tumor growth with no significant changes in body weight.

化学情報

CAS 番号 3035032-77-7
性状 Solid
分子量 508.91
分子式 C₂₂H₂₇BrClN₅S
Color White to off-white
SMILES

ClC1=CC=C2C(N(C3=CC=CC=C3S2)CCCC[N+]4(C[N@@](C5)C6)C[N@@]6C[N@@]5C4)=C1.[Br-]
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (196.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9650 mL

9.8249 mL

19.6498 mL

5 mM

0.3930 mL

1.9650 mL

3.9300 mL

10 mM

0.1965 mL

0.9825 mL

1.9650 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Johnson H, et al. Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer. J Med Chem. 2024 Oct 24;67(20):18070-18089. [Content Brief]

[2]. Hannah Johnson, et al.Sharma; Abstract 1655: Discovery of a novel PP2A activator as a potential therapeutic for FOLFOX resistant colon cancer. Cancer Res 1 April 2023; 83 (7_Supplement): 1655.

[3]. Hannah Johnson, et al. Abstract 7273: Small molecule activation of PP2A in the treatment of melanoma. Cancer Res 15 March 2024; 84 (6_Supplement): 7273.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9650 mL	9.8249 mL	19.6498 mL	49.1246 mL
	5 mM	0.3930 mL	1.9650 mL	3.9300 mL	9.8249 mL
	10 mM	0.1965 mL	0.9825 mL	1.9650 mL	4.9125 mL
	15 mM	0.1310 mL	0.6550 mL	1.3100 mL	3.2750 mL
	20 mM	0.0982 mL	0.4912 mL	0.9825 mL	2.4562 mL
	25 mM	0.0786 mL	0.3930 mL	0.7860 mL	1.9650 mL
	30 mM	0.0655 mL	0.3275 mL	0.6550 mL	1.6375 mL
	40 mM	0.0491 mL	0.2456 mL	0.4912 mL	1.2281 mL
	50 mM	0.0393 mL	0.1965 mL	0.3930 mL	0.9825 mL
	60 mM	0.0327 mL	0.1637 mL	0.3275 mL	0.8187 mL
	80 mM	0.0246 mL	0.1228 mL	0.2456 mL	0.6141 mL
	100 mM	0.0196 mL	0.0982 mL	0.1965 mL	0.4912 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

PPA24

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

GSK-3 アイソフォーム固有の製品をすべて表示

ERK アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

PPA24 関連分類

HY-163828 関連分類